CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Loncastuximab 可在 CAR-T 细胞治疗后进展的患者中实现缓解。
本研究评估了LOTIS-2试验中13例CAR-T 治疗后复发并接受loncastuximab治疗的DLBCL患者结局。
6例患者（46%）对loncastuximab治疗有应答，其中2例达到完全缓解（CR）。治疗后的总生存期、无进展生存期和应答持续时间中位数分别为8.2个月、1.4个月和8个月。
CAR-T 治疗后进展的患者仍可能对loncastuximab产生应答。在CD19未丢失的情况下，可以按序使用靶向CD19的治疗。
We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial.
Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively.
Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
MEMBER ACCOUNT
登录成功会直接打开下一页。
